Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Pipeline Review, H2 2018

  • ID: 4590361
  • Drug Pipelines
  • 57 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • BioCrea GmbH
  • Bristol-Myers Squibb Co
  • Cadent Therapeutics
  • Cerecor Inc
  • Johnson & Johnson
  • NeurOp Inc
  • MORE
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Pipeline Review, H2 2018

Summary:

According to the recently published report 'Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H2 2018'; Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) pipeline Target constitutes close to 14 molecules.

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Glutamate receptor subunit epsilon-2 or N-methyl D-aspartate receptor subtype 2B (NMDAR2B or NR2B) is a protein encoded by the GRIN2B gene. It is mediated by glycine. It acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them resulting in an irreversible neuronal death.

The report 'Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H2 2018' outlays comprehensive information on the Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 2, 7, 1 and 1 respectively.

Report covers products from therapy areas Central Nervous System, Cardiovascular and Dermatology which include indications Major Depressive Disorder, Treatment Resistant Depression, Acute Ischemic Stroke, Autism, Brain Ischemia, Burns, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Infantile Spasm (West Syndrome), Myocardial Infarction, Neurodegenerative Diseases, Neuropathic Pain, Obsessive-Compulsive Disorder, Orthostatic Hypotension, Pain, Subarachnoid Hemorrhage, Traumatic Brain Injury and Traumatic Spinal Cord Injury.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B)
  • The report reviews Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • BioCrea GmbH
  • Bristol-Myers Squibb Co
  • Cadent Therapeutics
  • Cerecor Inc
  • Johnson & Johnson
  • NeurOp Inc
  • MORE
Introduction

Report Coverage

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Overview

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Companies Involved in Therapeutics Development

BioCrea GmbH

Bristol-Myers Squibb Co

Cadent Therapeutics

Cerecor Inc

Johnson & Johnson

NeurOp Inc

Novartis AG

Shionogi & Co Ltd

UCB SA

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Drug Profiles

BMS-986163 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ifenprodil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-0808 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neu-2000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-10679 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-11948 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

radiprodil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rislenemdaz - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize NR2B for Depression - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated with Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize GRIN2B for Autism and Obsessive Compulsive Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NMDA Receptor 2B for Major Depressive Disorder and Treatment Resistant Depression - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NMDA2B for Chronic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NR2B for Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Dormant Products

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Discontinued Products

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Product Development Milestones

Featured News & Press Releases

Apr 12, 2018 : NeurOp Initiates Phase 1 Clinical Trial of NMDA Receptor Inhibitor NP1

Oct 17, 2017: Cadent Therapeutics Receives Milestone for the Initiation of Phase 1 Clinical Studies

Jul 24, 2017: NIH Awards NeurOp $3.5 Million to Support Phase 1 Clinical Trial of NMDA Inhibitor NP1

Nov 29, 2016: Cerecor Reports Top-Line Data from CERC-301 Phase 2 Study for Major Depressive Disorder

Sep 21, 2016: Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder

May 16, 2016: GNT Pharma Receives IND Approval for Phase II Clinical Trial for Stroke Patients with Endovascular Treatment with First in Class Multi-Target Neuroprotection Drug Neu

Jan 19, 2016: Cerecor Announces Publication Describing Antidepressant Activity of CERC-301 in Preclinical Model

Sep 03, 2015: Cerecor Initiates Phase 2 Study for CERC-301, an Antidepressant Product Candidate with Potential for Rapid Onset of Effect

Mar 20, 2015: Cerecor Provides Update on CERC-301 Development in Major Depressive Disorder

Oct 03, 2014: Cerecor to Present at 13th Annual BIO Investor Forum

Oct 02, 2014: NeurOp Receives Milestone Payment as Bristol-Myers Squibb Nominates NMDA Receptor Compound as Drug Development Candidate

Dec 02, 2013: MedAvante Central Ratings Selected For Cerecor Investigational MDD Study

Nov 25, 2013: Cerecor Receives Fast Track Designation for CERC-301 for the Treatment of Major Depressive Disorder

Nov 08, 2013: Cerecor Announces Initiation of Phase 2 Study for CERC-301, an Oral Rapid-acting Antidepressant Candidate

Jun 28, 2010: Forest And Gedeon Richter Announce Phase II Study Results Of Radiprodil For Treatment Of Diabetic Peripheral Neuropathic Pain

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by BioCrea GmbH, H2 2018

Pipeline by Bristol-Myers Squibb Co, H2 2018

Pipeline by Cadent Therapeutics, H2 2018

Pipeline by Cerecor Inc, H2 2018

Pipeline by Johnson & Johnson, H2 2018

Pipeline by NeurOp Inc, H2 2018

Pipeline by Novartis AG, H2 2018

Pipeline by Shionogi & Co Ltd, H2 2018

Pipeline by UCB SA, H2 2018

Dormant Projects, H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • BioCrea GmbH
  • Bristol-Myers Squibb Co
  • Cadent Therapeutics
  • Cerecor Inc
  • Johnson & Johnson
  • NeurOp Inc
  • Novartis AG
  • Shionogi & Co Ltd
  • UCB SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll